EUVIMEDEUVIMED entdecken
Crossref

Exploring Pyrazolo[3,4‐ b ]Pyridine and Spiro‐Oxindole Hybrids as Selective CDK2 or EGFR Inhibitors for Targeted Cancer Therapy: Design, Synthesis, and Molecular Modeling Insights

Ahmed K B A W Farouk iD, Aya A A Al-Tanany, Mohamed R Elnagar iD, Mohamed M Tawfik iD, Mohamed K El-Ashrey iD, Safinaz E-S Abbas iD, Hatem A Abdel-Aziz iD, Manal Abdel Fattah Ezzat iD

Drug Development Research · 2026-04 · 87 (2)

DOI: 10.1002/ddr.70263 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Development Research, online erschienen am 08.03.2026. Verfasst von Ahmed K B A W Farouk und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Cairo University, Cairo, Egypt. Hauptthemen laut MEDLINE: Spirooxindoles, Pyrazines, Drug Design, Antineoplastic Agents. Die Arbeit nennt 53 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

A new series of pyrazolo[3,4‐ b ]pyridine and spiro‐oxindole derivatives were rationally designed, synthesized, and biologically assessed as either CDK2 or EGFR inhibitors with potential anticancer activity. The CDK2 inhibitory evaluation of pyrazolo[3,4‐ b ]pyridines 6a–g and 7a–f revealed that compounds 6e , 7b , and 7c exhibited potent inhibition (IC₅₀ = 0.88, 1.89, and 1.23 μM, respectively), compared to roscovitine (IC₅₀ = 0.84 μM). Among the spiro‐oxindole derivatives 8a–d , compounds 8b and 8c demonstrated remarkable EGFR inhibition (IC₅₀ = 0.13 and 0.09 μM, respectively) and significant activity against mutant EGFR T790M (IC₅₀ = 0.32 and 0.14 μM) relative to gefitinib (IC₅₀ = 0.03 and 0.18 μM, respectively). Furthermore, compounds 6e and 8c exhibited selective cytotoxicity versus MCF‐7 and MDA‐MB231 cancer cells, respectively, with negligible cytotoxic effects on normal Vero cells. Flow cytometric analysis confirmed that compounds 6e and 8c induced G1‐phase cell cycle arrest and apoptosis in MCF‐7 and MDA‐MB‐231, respectively, accompanied by a pronounced increase in the Bax/Bcl‐2 ratio, with values of 12.15 and 16.93 fold, respectively. Molecular docking studies combined with molecular dynamics simulations further supported stable ligand–protein interactions within CDK2, EGFR, and mutant EGFR T790M active sites, with favorable binding energies and conformational stability throughout 100 ns trajectories. Collectively, these findings identify compounds 6e and 8c as promising lead scaffolds for further development of CDK2 or EGFR inhibitors with potent and selective anticancer properties.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SpirooxindolesPyrazinesDrug DesignAntineoplastic AgentsNeoplasmsCyclin-Dependent Kinase 2ErbB ReceptorsCell Line, TumorHumansVero CellsChlorocebus aethiopsAnimalsMolecular Docking SimulationMolecular Dynamics SimulationMolecular StructureBinding SitesApoptosis

Stichwörter der Autor:innen

CDK2EGFRanticancer activitypyrazolo[3,4‐b]pyridinespiro‐oxindole

Substanzen

pyrazolo(3,4-b)pyrazineSpirooxindolesPyrazinesAntineoplastic AgentsCyclin-Dependent Kinase 2ErbB Receptors

Autor:innen und Institutionen

  • Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Cairo University, Cairo, Egypt.
  • School of Life and Medical Sciences, University of Hertfordshire Hosted by Global Academic Foundation, Cairo, Egypt.
  • Postgraduate Program of Pharmaceutical Chemistry, Faculty of Pharmacy, Cairo University, Cairo, Egypt.
  • Department of Central Administration of Pharmaceutical Policies and Market Access, Egyptian Drug Authority, Cairo, Egypt.
  • Department of Pharmacology and Toxicology, Faculty of Pharmacy, Al-Azhar University, Cairo, Egypt.
  • Department of Pharmacology, College of Pharmacy, The Islamic University, Najaf, Iraq.

ORCID-Profile: Ahmed K B A W Farouk, Mohamed R Elnagar, Mohamed M Tawfik, Mohamed K El-Ashrey, Safinaz E-S Abbas, Hatem A Abdel-Aziz, Manal Abdel Fattah Ezzat

Zitieren

APA

Farouk, A. K. B. A. W., Al-Tanany, A. A. A., Elnagar, M. R., Tawfik, M. M., El-Ashrey, M. K., Abbas, S. E., Abdel-Aziz, H. A., & Ezzat, M. A. F. (2026). Exploring Pyrazolo[3,4‐ b ]Pyridine and Spiro‐Oxindole Hybrids as Selective CDK2 or EGFR Inhibitors for Targeted Cancer Therapy: Design, Synthesis, and Molecular Modeling Insights. Drug Development Research, 87(2). https://doi.org/10.1002/ddr.70263

Vancouver

Farouk AKBAW, Al-Tanany AAA, Elnagar MR, Tawfik MM, El-Ashrey MK, Abbas SE, et al. Exploring Pyrazolo[3,4‐ b ]Pyridine and Spiro‐Oxindole Hybrids as Selective CDK2 or EGFR Inhibitors for Targeted Cancer Therapy: Design, Synthesis, and Molecular Modeling Insights. Drug Development Research. 2026;87(2). doi:10.1002/ddr.70263

BibTeX
@article{Farouk2026,
  author = {Farouk, Ahmed K B A W and Al-Tanany, Aya A A and Elnagar, Mohamed R and Tawfik, Mohamed M and El-Ashrey, Mohamed K and Abbas, Safinaz E-S and Abdel-Aziz, Hatem A and Ezzat, Manal Abdel Fattah},
  title = {Exploring Pyrazolo[3,4‐ b ]Pyridine and Spiro‐Oxindole Hybrids as Selective CDK2 or EGFR Inhibitors for Targeted Cancer Therapy: Design, Synthesis, and Molecular Modeling Insights},
  journal = {Drug Development Research},
  year = {2026},
  volume = {87},
  number = {2},
  doi = {10.1002/ddr.70263}
}
Kostenlos starten →